Thyrocare Technologies Ltd Share Price – NSE  / BSE

Healthcare, Small Cap

Revenue from operations grew by 19.99% year on year (YoY) to Rs 177.36 crore in the quarter ended 30 September 2024.

Profit before tax in Q2 FY25 stood at Rs 36.78 crore, up 30.10% as against Rs 28.27 crore posted in same quarter last year.

Total expenses rose 16.88% YoY to Rs 142.90 crore during the quarter. Cost of materials and services consumed was at Rs 50.12 crore (up 16.34% YoY) while employee benefits expense stood at Rs 29.49 crore (up 8.98%) during the period under review.

The company's revenue from Diagnostic Testing Services was at Rs 161.92 crore (up 18.40% YoY) while revenue from Imaging Services stood at Rs 14.15 crore (up 20.83% YoY) in Q1 FY25.

EBITDA improved 28% YoY to Rs 48.2 crore in September 2024 quarter from Rs 37.6 crore reported in corresponding period previous year. EBITDA margin increased to 27% in Q2 FY25 as compared to 25% reported in the corresponding quarter last fiscal.

On half year basis, the company’s net profit jumped 35.06% to Rs 50.84 crore on 18.16% rise in revenue to Rs 334.27 crore in H1 FY25 over H1 FY24.

Thyrocare Technologies is engaged in the healthcare industry and is involved in providing quality diagnostic services at affordable costs to patients, laboratories and hospitals in India.

The counter has hit a 52-week high at Rs 957.95 in today's intra-day session.

Powered by Capital Market - Live News

Net profit of Thyrocare Technologies rose 31.12% to Rs 26.67 crore in the quarter ended September 2024 as against Rs 20.34 crore during the previous quarter ended September 2023. Sales rose 19.84% to Rs 177.36 crore in the quarter ended September 2024 as against Rs 148.00 crore during the previous quarter ended September 2023.

Powered by Capital Market - Live News

Thyrocare Technologies will hold a meeting of the Board of Directors of the Company on 23 October 2024.

Powered by Capital Market - Live News

Thyrocare Technologies announced the cessation of Neetin Shivajirao Desai (DIN No: 02622364) as Independent Director of the company with effect from 19 September 2024 on completion of second term.

Powered by Capital Market - Live News